Am J Physiol Cell Physiol Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Cell Physiol 292: C987-C995, 2007. First published August 30, 2006; doi:10.1152/ajpcell.00406.2006
0363-6143/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/3/C987    most recent
00406.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kryczek, I.
Right arrow Articles by Zou, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kryczek, I.
Right arrow Articles by Zou, W.

INVITED REVIEW

Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis

Ilona Kryczek,1 Shuang Wei,1 Evan Keller,2 Rebecca Liu,3 and Weiping Zou1

Departments of 1Surgery, 2Urology, and 3Obstetrics and Genecology, University of Michigan, Ann Arbor, Michigan

The chemokine stroma-derived factor (SDF-1/CXCL12) plays multiple roles in tumor pathogenesis. It has been demonstrated that CXCL12 promotes tumor growth and malignancy, enhances tumor angiogenesis, participates in tumor metastasis, and contributes to immunosuppressive networks within the tumor microenvironment. Therefore, it stands to reason that the CXCL12/CXCR4 pathway is an important target for the development of novel anti-cancer therapies. In this review, we consider the pathological nature and characteristics of the CXCL12/CXCR4 pathway in the tumor microenvironment. Strategies for therapeutically targeting the CXCL12/CXCR4 axis also are discussed.

migration; immune suppression; tumor angiogenesis; tumor metastasis; stem cells



Address for reprint requests and other correspondence: W. Zou, Univ. of Michigan School of Medicine, C560B MSRB II, 1150 W. Medical Center Dr., Ann Arbor, MI 48109-0669 (e-mail: wzou{at}umich.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.